From Wikipedia, the free encyclopedia
Jump to: navigation, search
ADAM metallopeptidase domain 8
Available structures
PDB Ortholog search: PDBe, RCSB
Symbols ADAM8 ; CD156; CD156a; MS2
External IDs OMIM602267 MGI107825 HomoloGene74384 IUPHAR: 1656 GeneCards: ADAM8 Gene
EC number 3.4.24.-
RNA expression pattern
PBB GE ADAM8 205180 s at tn.png
PBB GE ADAM8 205179 s at tn.png
More reference expression data
Species Human Mouse
Entrez 101 11501
Ensembl ENSG00000151651 ENSMUSG00000025473
UniProt P78325 Q05910
RefSeq (mRNA) NM_001109 NM_001291066
RefSeq (protein) NP_001100 NP_001277995
Location (UCSC) Chr 10:
133.26 – 133.28 Mb
Chr 7:
139.98 – 139.99 Mb
PubMed search [1] [2]

A Disintegrin and metalloproteinase domain-containing protein 8 is an enzyme that in humans is encoded by the ADAM8 gene.[1][2]


This gene encodes a member of the ADAM (a disintegrin and metalloproteinase domain) family. Members of this family are membrane-anchored proteins structurally related to snake venom disintegrins, and have been implicated in a variety of biological processes involving cell-cell and cell-matrix interactions, including fertilization, muscle development, and neurogenesis. The protein encoded by this gene may be involved in cell adhesion during neurodegeneration.[2]

See also[edit]


  1. ^ Yoshiyama K, Higuchi Y, Kataoka M, Matsuura K, Yamamoto S (Apr 1997). "CD156 (human ADAM8): expression, primary amino acid sequence, and gene location". Genomics 41 (1): 56–62. doi:10.1006/geno.1997.4607. PMID 9126482. 
  2. ^ a b "Entrez Gene: ADAM8 ADAM metallopeptidase domain 8". 

Further reading[edit]

  • Yamamoto S, Higuchi Y, Yoshiyama K, Shimizu E, Kataoka M, Hijiya N et al. (Jun 1999). "ADAM family proteins in the immune system". Immunology Today 20 (6): 278–84. doi:10.1016/S0167-5699(99)01464-4. PMID 10354553. 
  • Schlomann U, Rathke-Hartlieb S, Yamamoto S, Jockusch H, Bartsch JW (Nov 2000). "Tumor necrosis factor alpha induces a metalloprotease-disintegrin, ADAM8 (CD 156): implications for neuron-glia interactions during neurodegeneration". The Journal of Neuroscience 20 (21): 7964–71. PMID 11050116. 
  • Amour A, Knight CG, English WR, Webster A, Slocombe PM, Knäuper V et al. (Jul 2002). "The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs". FEBS Letters 524 (1-3): 154–8. doi:10.1016/S0014-5793(02)03047-8. PMID 12135759. 
  • Ishikawa N, Daigo Y, Yasui W, Inai K, Nishimura H, Tsuchiya E et al. (Dec 2004). "ADAM8 as a novel serological and histochemical marker for lung cancer". Clinical Cancer Research 10 (24): 8363–70. doi:10.1158/1078-0432.CCR-04-1436. PMID 15623614. 
  • Foley SC, Mogas AK, Olivenstein R, Fiset PO, Chakir J, Bourbeau J et al. (Apr 2007). "Increased expression of ADAM33 and ADAM8 with disease progression in asthma". The Journal of Allergy and Clinical Immunology 119 (4): 863–71. doi:10.1016/j.jaci.2006.12.665. PMID 17339047. 
  • Gómez-Gaviro M, Domínguez-Luis M, Canchado J, Calafat J, Janssen H, Lara-Pezzi E et al. (Jun 2007). "Expression and regulation of the metalloproteinase ADAM-8 during human neutrophil pathophysiological activation and its catalytic activity on L-selectin shedding". Journal of Immunology 178 (12): 8053–63. doi:10.4049/jimmunol.178.12.8053. PMID 17548643. 
  • Valkovskaya N, Kayed H, Felix K, Hartmann D, Giese NA, Osinsky SP et al. (2008). "ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer". Journal of Cellular and Molecular Medicine 11 (5): 1162–74. doi:10.1111/j.1582-4934.2007.00082.x. PMID 17979891. 

External links[edit]

This article incorporates text from the United States National Library of Medicine, which is in the public domain.